Suppr超能文献

HIV阳性女性原位宫颈癌的治疗。

Treatment of cervical carcinoma in situ in HIV positive women.

作者信息

Williams F S, Roure R M, Till M, Vogler M, Del Priore G

机构信息

Division of Gynecologic Oncology, New York University School of Medicine, New York, NY, USA.

出版信息

Int J Gynaecol Obstet. 2000 Nov;71(2):135-9. doi: 10.1016/s0020-7292(00)00283-6.

Abstract

OBJECTIVES

To evaluate the safety and effectiveness of hysterectomy vs. cone biopsy in HIV seropositive patients with carcinoma in situ of the cervix (CIS).

METHODS

We performed a retrospective case-control study of all HIV seropositive patients diagnosed with carcinoma in situ of the cervix from 1989 to 1995. A control group of HIV(-) women with CIS was also ascertained matched for date of diagnosis of CIS, race and age.

RESULTS

There were 439 patients with CIS, of which 45 were HIV seropositive (10.3%). Nine were treated by hysterectomy, 30 by cone biopsy, and six remained untreated. Overall, 63% of HIV(+) patients did not receive any follow-up Pap smear (44% of hysterectomy patients, 50% of cone biopsy patients, and 83% of untreated patients; chi(2) P=0.41). According to Pap smear results, 67% (10/15) cone biopsy patients and 60% (3/5) hysterectomy patients had an abnormal Pap smear after treatment (P=0.9). Median time to recurrence was 12 months in hysterectomy patients vs. 14 months in cone biopsy patients. Deaths occurred in 22% of hysterectomy patients, 17% of cone biopsy patients, and 50% of untreated patients, none due to cervical cancer. Median time to death from presentation was 27.5 months for hysterectomy patients, 11 months for cone biopsy patients, and 7 months for untreated patients (P<0.05). There were no complications in the hysterectomy group, however, two patients were readmitted after cone biopsy for bleeding. When compared to HIV(-) women with CIS, HIV(+) patients were more likely to be treated by hysterectomy (chi(2) P=0.01).

CONCLUSION

All patients diagnosed with CIS should be counseled regarding HIV prevention and testing because of a significant seropositive rate. Compliance with gynecologic follow-up is very poor in this patient population. Special efforts should be made to enhance compliance. Cone biopsy and hysterectomy appear to be equally safe and effective in the treatment of CIS. CIS in HIV patients is a poor prognostic indicator for death from any cause.

摘要

目的

评估子宫切除术与宫颈锥切活检术对HIV血清学阳性的宫颈原位癌(CIS)患者的安全性和有效性。

方法

我们对1989年至1995年期间所有诊断为宫颈原位癌的HIV血清学阳性患者进行了一项回顾性病例对照研究。还确定了一组HIV(-)的宫颈原位癌女性作为对照组,根据宫颈原位癌诊断日期、种族和年龄进行匹配。

结果

共有439例宫颈原位癌患者,其中45例为HIV血清学阳性(10.3%)。9例行子宫切除术,30例行宫颈锥切活检术,6例未接受治疗。总体而言,63%的HIV(+)患者未接受任何后续巴氏涂片检查(子宫切除术患者中44%,宫颈锥切活检术患者中50%,未治疗患者中83%;卡方检验P = 0.41)。根据巴氏涂片结果,67%(10/15)的宫颈锥切活检术患者和60%(3/5)的子宫切除术患者治疗后巴氏涂片异常(P = 0.9)。子宫切除术患者复发的中位时间为12个月,宫颈锥切活检术患者为14个月。子宫切除术患者中有22%死亡,宫颈锥切活检术患者中有17%死亡,未治疗患者中有50%死亡,均非死于宫颈癌。子宫切除术患者从确诊到死亡的中位时间为27.5个月,宫颈锥切活检术患者为11个月,未治疗患者为7个月(P<0.05)。子宫切除术组无并发症,然而,2例宫颈锥切活检术后患者因出血再次入院。与HIV(-)的宫颈原位癌女性相比,HIV(+)患者更有可能接受子宫切除术(卡方检验P = 0.01)。

结论

由于血清学阳性率较高,所有诊断为宫颈原位癌的患者均应接受HIV预防和检测咨询。该患者群体对妇科随访的依从性非常差。应特别努力提高依从性。宫颈锥切活检术和子宫切除术在治疗宫颈原位癌方面似乎同样安全有效。HIV患者的宫颈原位癌是任何原因导致死亡的不良预后指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验